<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04420234</url>
  </required_header>
  <id_info>
    <org_study_id>SYSS-Remitch-HD-I-01</org_study_id>
    <nct_id>NCT04420234</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetics and Safety Study of Narfurine Hydrochloride Orally Disintegrating Tablets</brief_title>
  <official_title>A Single-center Phase I Clinical Study Evaluating the Pharmacokinetics and Safety of Single and Multiple Oral Administration of Narfurine Hydrochloride Orally Disintegrating Tablets in Chinese Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shenyang Sunshine Pharmaceutical Co., LTD.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital of Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Main objective: To evaluate the pharmacokinetics of single and multiple oral administration
      of narfurine hydrochloride orally disintegrating tablets in Chinese healthy adult subjects.

      Secondary objective: To evaluate the safety profile of single and multiple oral
      administration of narfurine hydrochloride orally disintegrating tablets in Chinese healthy
      adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC AUC</measure>
    <time_frame>Day1 to Day13</time_frame>
    <description>Area Under the Plasma Concentration-time Curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day1 to Day13</time_frame>
    <description>Maximum Observed Plasma Concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day1 to Day13</time_frame>
    <description>Time to Reach the Maximum Plasma Concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2</measure>
    <time_frame>Day1 to Day13</time_frame>
    <description>Elimination half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Kel</measure>
    <time_frame>Day1 to Day13</time_frame>
    <description>Elimination rate constant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F CL/F</measure>
    <time_frame>Day1 to Day13</time_frame>
    <description>Apparent clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vd/F</measure>
    <time_frame>Day1 to Day13</time_frame>
    <description>Apparent distribution volume based on terminal elimination phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRT</measure>
    <time_frame>Day1 to Day13</time_frame>
    <description>Mean residence time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Css_max</measure>
    <time_frame>Day1 to Day13</time_frame>
    <description>Steady state peak concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Css_min</measure>
    <time_frame>Day1 to Day13</time_frame>
    <description>Steady state Valley concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Css_av</measure>
    <time_frame>Day1 to Day13</time_frame>
    <description>Steady state average concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DF</measure>
    <time_frame>Day1 to Day13</time_frame>
    <description>Volatility index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerance indicators</measure>
    <time_frame>Day1 to Day13</time_frame>
    <description>AE and SAE</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Improvement of Pruritus in Hemodialysis Patients</condition>
  <arm_group>
    <arm_group_label>Pharmacokinetics study of single and multiple administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the study session, 30 healthy subjects will be administered a single and multiple dose of narfurine hydrochloride orally disintegrating tablets 5 µg (2.5 µg/table) to evaluate the pharmacokinetic parameters and the safety profile.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>narfurine hydrochloride orally disintegrating tablets</intervention_name>
    <description>Subjects swallowed 2 tablets of test drug (2.5 µg/tablet) with saliva at about 8:00 AM on D1; swallowed 2 tablets of test drug (2.5 µg/tablet) with saliva at about 8:00 AM starting on D4. Dosing for 7 consecutive days (D10 last dose in the morning).</description>
    <arm_group_label>Pharmacokinetics study of single and multiple administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years old &lt;= age &lt;= 40 years old, male or female;

          2. Weight: male &gt;= 50 kg, female &gt;= 45 kg; body mass index (BMI) in the range of 19-26 kg
             / m2 (including 19 and 26);

          3. Important indicators including physical examination, vital signs examination,
             electrocardiogram examination, laboratory examination, and chest X-ray examination are
             normal or within the acceptable range of the sponsors or researchers;

          4. During the trial and within 3 months after the last medication, there is no parenting
             plan and reliable contraceptive measures could be taken;

          5. Fully understand the purpose and requirements of this trial, voluntarily participate
             in clinical trials and sign a written informed consent form, and can complete the
             entire trial process according to the trial requirements.

        Exclusion Criteria:

          1. Those who are known to have a history of allergies, allergic diseases or allergies to
             the test preparation and any of its components or related preparations;

          2. Those who have a clear medical history of the central nervous system, cardiovascular
             system, digestive system, respiratory system, urinary system, blood system, metabolic
             disorders or serious infections and serious injuries, or other diseases that are not
             suitable for participating in clinical trials (such as history of mental illness,
             etc.)

          3. Those who have donated blood or lost blood &gt;= 400mL within 3 months before enrollment;

          4. Those who have taken any drugs (including prescription drugs and over-the-counter
             drugs), vitamins, and Chinese herbal medicines within 2 weeks before screening;

          5. Those who have participated in clinical trials of other drugs or medical devices
             within 3 months before being selected;

          6. Those who is or was a drug addict or positive in drug abuse screening test;

          7. Those who is or was an alcoholic (drinking more than 14 standard units per week. 1
             standard unit contains 14g alcohol, such as 360mL beer or 45mL spirits with 40%
             alcohol or 150mL wine), or positive in urine alcohol test.

          8. Smokers or those with an average daily smoking volume of more than 5 cigarettes within
             3 months before screening, and those with a positive nicotine test;

          9. Those who is positive in Hepatitis B surface antigen (HBsAg), HCV antibody, Treponema
             pallidum antibody and HIV antibody;

         10. Female subjects who are in the lactation period or is positive in the pregnancy test
             during the screening period or clinical trial;

         11. Those who have used any drugs that is CYP3A4 inhibitor or inducer within 4 weeks
             before signing the informed consent form, see Appendix 3 for details;

         12. People with long-term insomnia and those with the habit of taking sleeping pills;

         13. People with habitual constipation;

         14. Those who is diagnosed abnormal or with clinical significance in physical examination,
             vital signs examination, electrocardiogram or clinical laboratory examination, etc.,

         15. Those who have undergone surgery that can affect the absorption, distribution,
             metabolism, excretion of drugs, or have any gastrointestinal diseases that may affect
             the absorption of drugs, or those who are determined by the investigator to be
             unsuitable for enrollment;

         16. Those who consume excessive amounts of tea, coffee and / or caffeinated beverages
             (more than 8 cups, 1 cup = 250mL) every day within 30 days before screening

         17. Those who took grapefruit or grapefruit juice and drinks or foods containing St.
             John's wort (hypericum perforatum), ginseng, ginkgo, valerian, and echinacea within 48
             hours before administration;

         18. Those who is diagnosed abnormal or have clinical significance by researchers in the
             chest X-ray examination;

         19. Those who develop new diseases during the pre-study screening stage or before study
             medication;

         20. Those who cannot tolerate venipuncture blood collection;

         21. Those who are thought to be unsuitable for participating in the trial by the
             researchers because of other factors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jian liu, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital,ZheJiang Univercity</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>jian liu, master</last_name>
    <phone>+86-13958054006</phone>
    <email>lindaliu87@zju.edu.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>you zhai, master</last_name>
    <phone>+86-1395802759</phone>
    <email>youzhai@yeah.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital,ZheJiang Univercity</name>
      <address>
        <city>Hanzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 4, 2020</study_first_submitted>
  <study_first_submitted_qc>June 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>narfurine hydrochloride orally disintegrating tablets</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

